Mastocytosis in Pregnancy

Area of Science:

• Hematology
• Oncology
• Obstetrics

Background:

• Mastocytosis is a rare neoplastic disease characterized by mast cell proliferation and activation.
• Approximately one-third of pregnant patients with mastocytosis experience symptom exacerbation.
• Current treatment strategies focus on symptom management using antimediator therapies.

Purpose of the Study:

• To review the management of mastocytosis in pregnant patients.
• To highlight considerations for medication selection during labor and delivery.
• To identify medications that may require caution or avoidance in this population.

Main Methods:

• Literature review of mastocytosis in pregnancy.
• Analysis of treatment guidelines for mastocytosis.
• Evaluation of medication safety profiles during labor and delivery.

Main Results:

• Symptom worsening occurs in about 33% of pregnant mastocytosis patients.
• Antimediator therapy (antihistamines, glucocorticoids, epinephrine) is the mainstay of treatment.
• Certain medications like codeine, morphine, NSAIDs, and vancomycin may need cautious use or avoidance if not previously tolerated.

Conclusions:

• Mastocytosis management during pregnancy requires careful consideration of antimediator therapies.
• Medication choices for labor and delivery must account for potential risks and patient history.
• Individualized treatment plans are essential for pregnant patients with mastocytosis.